Alumis Inc
Research Alumis Inc (ALMS) on Bullrun: market cap USD 3.46B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerALMS
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 3.46B
- Financial periodFY2025
- RevenueUSD 24.05M
- Net income-USD 243.33M
- Free cash flow-USD 370.18M
Valuation Snapshot
latest market cap is USD 3.46B.
About Alumis Inc
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases.
Frequently asked questions
What is Alumis Inc's market cap?
Alumis Inc's market capitalization is USD 3.46B.
What does Alumis Inc do?
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus;